PMID- 33796846
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210403
IS  - 2589-0042 (Electronic)
IS  - 2589-0042 (Linking)
VI  - 24
IP  - 4
DP  - 2021 Apr 23
TI  - GPR52 accelerates fatty acid biosynthesis in a ligand-dependent manner in 
      hepatocytes and in response to excessive fat intake in mice.
PG  - 102260
LID - 10.1016/j.isci.2021.102260 [doi]
LID - 102260
AB  - Gpr52 is an orphan G-protein-coupled receptor of unknown physiological function. 
      We found that Gpr52-deficient (Gpr52 (-/-) ) mice exhibit leanness associated 
      with reduced liver weight, decreased hepatic de novo lipogenesis, and enhanced 
      insulin sensitivity. Treatment of the hepatoma cell line HepG2 cells with c11, 
      the synthetic GPR52 agonist, increased fatty acid biosynthesis, and GPR52 
      knockdown (KD) abolished the lipogenic action of c11. In addition, c11 induced 
      the expressions of lipogenic enzymes (SCD1 and ELOVL6), whereas these inductions 
      were attenuated by GPR52-KD. In contrast, cholesterol biosynthesis was not 
      increased by c11, but its basal level was significantly suppressed by GPR52-KD. 
      High-fat diet (HFD)-induced increase in hepatic expression of Pparg2 and its 
      targets (Scd1 and Elovl6) was absent in Gpr52 (-/-) mice with alleviated 
      hepatosteatosis. Our present study showed that hepatic GPR52 promotes the 
      biosynthesis of fatty acid and cholesterol in a ligand-dependent and a 
      constitutive manner, respectively, and Gpr52 participates in HFD-induced fatty 
      acid synthesis in liver.
CI  - (c) 2021 The Authors.
FAU - Wada, Mitsuo
AU  - Wada M
AD  - Department of Medical Physiology, Chiba University, Graduate School of Medicine, 
      Chiba 260-8670, Japan.
AD  - Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research 
      Institute, Japan Tobacco Inc., Yokohama 236-0004, Japan.
FAU - Yukawa, Kayo
AU  - Yukawa K
AD  - Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research 
      Institute, Japan Tobacco Inc., Yokohama 236-0004, Japan.
FAU - Ogasawara, Hiroyuki
AU  - Ogasawara H
AD  - Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research 
      Institute, Japan Tobacco Inc., Yokohama 236-0004, Japan.
FAU - Suzawa, Koichi
AU  - Suzawa K
AD  - Central Pharmaceutical Research Institute, Japan Tobacco Inc., Takatsuki 
      569-1125, Japan.
FAU - Maekawa, Tatsuya
AU  - Maekawa T
AD  - Central Pharmaceutical Research Institute, Japan Tobacco Inc., Takatsuki 
      569-1125, Japan.
FAU - Yamamoto, Yoshihisa
AU  - Yamamoto Y
AD  - Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research 
      Institute, Japan Tobacco Inc., Yokohama 236-0004, Japan.
FAU - Ohta, Takeshi
AU  - Ohta T
AD  - Laboratory of Animal Physiology and Functional Anatomy, Graduate School of 
      Agriculture, Kyoto University, Kyoto 606-8502, Japan.
FAU - Lee, Eunyoung
AU  - Lee E
AD  - Department of Medical Physiology, Chiba University, Graduate School of Medicine, 
      Chiba 260-8670, Japan.
FAU - Miki, Takashi
AU  - Miki T
AD  - Department of Medical Physiology, Chiba University, Graduate School of Medicine, 
      Chiba 260-8670, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210302
PL  - United States
TA  - iScience
JT  - iScience
JID - 101724038
PMC - PMC7995607
OTO - NOTNLM
OT  - Human Metabolism
OT  - Molecular Biology
COIS- The authors declare no competing interests.
EDAT- 2021/04/03 06:00
MHDA- 2021/04/03 06:01
PMCR- 2021/03/02
CRDT- 2021/04/02 06:39
PHST- 2020/11/09 00:00 [received]
PHST- 2021/02/06 00:00 [revised]
PHST- 2021/02/26 00:00 [accepted]
PHST- 2021/04/02 06:39 [entrez]
PHST- 2021/04/03 06:00 [pubmed]
PHST- 2021/04/03 06:01 [medline]
PHST- 2021/03/02 00:00 [pmc-release]
AID - S2589-0042(21)00228-5 [pii]
AID - 102260 [pii]
AID - 10.1016/j.isci.2021.102260 [doi]
PST - epublish
SO  - iScience. 2021 Mar 2;24(4):102260. doi: 10.1016/j.isci.2021.102260. eCollection 
      2021 Apr 23.